DekaBank Deutsche Girozentrale raised its holdings in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 21.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,100 shares of the biotechnology company’s stock after acquiring an additional 2,700 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Aimmune Therapeutics were worth $423,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the company. Cable Hill Partners LLC grew its stake in shares of Aimmune Therapeutics by 81.7% during the 1st quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 500 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in shares of Aimmune Therapeutics by 28.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 36,802 shares of the biotechnology company’s stock worth $823,000 after acquiring an additional 8,251 shares in the last quarter. Manchester Capital Management LLC bought a new position in shares of Aimmune Therapeutics during the 1st quarter worth approximately $27,000. Great West Life Assurance Co. Can grew its stake in shares of Aimmune Therapeutics by 63.7% during the 1st quarter. Great West Life Assurance Co. Can now owns 5,426 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 2,111 shares in the last quarter. Finally, Raymond James & Associates grew its stake in shares of Aimmune Therapeutics by 16.3% in the first quarter. Raymond James & Associates now owns 53,964 shares of the biotechnology company’s stock valued at $1,206,000 after buying an additional 7,581 shares in the last quarter. 76.13% of the stock is owned by institutional investors.
NASDAQ:AIMT opened at $20.22 on Friday. Aimmune Therapeutics Inc has a 1-year low of $19.25 and a 1-year high of $36.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.65 and a current ratio of 7.65.
Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.07. On average, equities research analysts predict that Aimmune Therapeutics Inc will post -3.77 EPS for the current fiscal year.
Several research firms recently weighed in on AIMT. BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 21st. Cantor Fitzgerald reissued a “buy” rating on shares of Aimmune Therapeutics in a research note on Thursday, April 11th. Credit Suisse Group began coverage on shares of Aimmune Therapeutics in a research note on Tuesday, May 21st. They issued an “outperform” rating and a $30.00 target price for the company. Wedbush set a $79.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Friday, May 24th. Finally, Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a research note on Thursday. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Aimmune Therapeutics currently has an average rating of “Buy” and an average target price of $46.43.
ILLEGAL ACTIVITY WARNING: “DekaBank Deutsche Girozentrale Raises Stake in Aimmune Therapeutics Inc (NASDAQ:AIMT)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2019/06/14/dekabank-deutsche-girozentrale-raises-stake-in-aimmune-therapeutics-inc-nasdaqaimt.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Read More: Capital gains and your 401(k) or IRA
Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.